Corvus Pharmaceuticals (CRVS) Research & Development (2015 - 2026)
Corvus Pharmaceuticals' Research & Development was $15.96 million in Q2 2026, up 102.8% from $7.87 million a year earlier and up 42.9% from the prior quarter.
Powered by 
Analysis
Corvus Pharmaceuticals (CRVS) Research & Development (2015 - 2026) Analysis & Trends
On a trailing twelve-month basis, Corvus Pharmaceuticals' Research & Development was $43.47 million through Jun 30, 2026, up 76.2% year-over-year; for FY2023, it was $16.53 million, down 32.5% from FY2022.
- Research & Development has now declined for six consecutive years, with a five-year compound annual growth rate of -15.6% (FY2018 to FY2023).
- In earlier years, Research & Development was $24.47 million in FY2022 (-16.0%), $29.12 million in FY2021 (-8.5%), $31.83 million in FY2020 (-16.2%) and $37.98 million in FY2019 (-1.6%).
- The Q2 2026 figure marks the highest quarterly Research & Development in data going back to Q1 2015.
- The best year-over-year quarter for Research & Development over five years was Q2 2026 (growth of 102.8%); the worst was Q3 2023 (a decline of 61.7%).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,146.94 Bn | 1,115.53 Bn | 19.71 Bn | 3.82 Bn |
| 2 | Johnson & Johnson | 624.96 Bn | 543.49 Bn | 17.26 Bn | 3.65 Bn |
| 3 | AbbVie | 510.15 Bn | 483.27 Bn | 12.70 Bn | 2.34 Bn |
| 4 | Merck | 366.13 Bn | 320.51 Bn | 12.21 Bn | 9.74 Bn |
| 5 | Novartis Ag | 297.75 Bn | 261.74 Bn | 11.24 Bn | 2.85 Bn |
| 6 | Astrazeneca | 261.93 Bn | 235.62 Bn | 12.86 Bn | 4.05 Bn |
| 7 | Amgen | 236.51 Bn | 191.91 Bn | 7.24 Bn | 1.87 Bn |
| 8 | Gilead Sciences | 194.27 Bn | 168.47 Bn | 6.22 Bn | 1.76 Bn |
| 9 | Pfizer | 171.74 Bn | 118.39 Bn | 10.94 Bn | 2.81 Bn |
| 10 | Corvus Pharmaceuticals | 943.08 Mn | 431.52 Mn | - | 15.96 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 15.96 Mn |
| Mar 31, 2026 | 11.18 Mn |
| Dec 31, 2025 | 9.94 Mn |
| Sep 30, 2025 | 8.45 Mn |
| Jun 30, 2025 | 7.87 Mn |
| Mar 31, 2025 | 7.45 Mn |
| Dec 31, 2024 | 5.97 Mn |
| Sep 30, 2024 | 5.22 Mn |
| Jun 30, 2024 | 4.11 Mn |
| Mar 31, 2024 | 4.08 Mn |
| Dec 31, 2023 | 4.00 Mn |
| Sep 30, 2023 | 3.97 Mn |
| Jun 30, 2023 | 3.97 Mn |
| Mar 31, 2023 | 4.59 Mn |
| Dec 31, 2022 | 4.08 Mn |
| Sep 30, 2022 | 10.37 Mn |
| Jun 30, 2022 | 4.92 Mn |
| Mar 31, 2022 | 5.10 Mn |
| Dec 31, 2021 | 4.79 Mn |
| Sep 30, 2021 | 6.99 Mn |
API Access
Corvus Pharmaceuticals Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=CRVS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "CRVS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=CRVS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();